GeneProt Expands its Proteomic Capabilities Through a New Scientific Agreement
GeneProt amends its collaboration with Novartis Pharma
In October 2000, GeneProt and Novartis entered into a four-year collaboration to perform large scale proteomic studies for different therapeutic areas. Under the new collaboration agreement, GeneProt will continue to use its large scale proteomics platform and will accelerate the delivery of proteins to Novartis for further biological evaluation.
GeneProt will also take advantage of the new platforms it has developed to perform innovative proteomics such as accelerated studies on non-pooled samples, or pharmacoproteomics. Financial details were not disclosed.
"It is necessary to follow industrial-scale discovery with industrial-scale biological evaluation and also to stay at the forefront of a rapidly evolving industrial environment. We are pleased to offer these cutting edge proteomics services to Novartis. We look forward to continued collaboration with Novartis to leverage our combined expertise in an effort to accelerate the pace of pharmaceutical innovation," said Bertrand Damour, GeneProt's President and CEO.
Most read news
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.